Realistic Expectations: The Management of Severe Alzheimer Disease
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by a loss of memory and cognition, a decline in ability to perform activities of daily living, changes in personality and behavior, and an increase in resource utilization and medical care. The natural course of AD can be viewed as a gradual loss of independence divided into several stages (mild, moderate, and severe) that ultimately leaves the patient under the supervision of a caregiver. Acetylcholinesterase inhibitors are the most widely accepted and proven approach to the treatment of mild to moderate AD. However, management of patients with severe AD poses challenges to physicians because there are only limited treatment options for these patients. This article provides overviews of the natural history, current therapy, and diagnostic scales of AD, focusing on management of patients with severe AD. In addition, a brief summary of the existing clinical trials conducted in severe AD is presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · cited 1×
“3).(22) Patients were randomly assigned to receive sele-”
MethodThe cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 1×
“Therefore, pharmacologic enhancement of cholinergic function may stabilize or improve cognitive function and may affect behavior and daily functioning in a positive manner.(5,6) To date, inhibition of acetylcholinesterase (AChE), the enzyme responsible for the breakdown of ACh, represents the most established treatmen…”
BackgroundRosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Doody, R. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.427 · Cited by 362 · cited 2×
“Evidence of the long-term cognitive benefits of donepezil comes from a study conducted by Doody et al.18 This multicenter, 144-week, open-label extension of two earlier doubleblind studies (of 15 and 30 weeks’ duration, followed by a placebo washout period of 3 or 6 weeks, respectively) evaluated the change from basel…”
BackgroundFarlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J. (2000) · European Neurology · doi:10.1159/000008243 · Cited by 332 · cited 3×
“The efficacy of treatment with rivastigmine for up to 12 months was evaluated in another open-label extension of an earlier 6-month, randomized, double-blind, placebocontrolled study.(13) In the initial double-blind phase, patients were treated with rivastigmine at doses of 1 to 4 mg/day, 6 to 12 mg/day, or placebo.”
BackgroundMethodInfluentialChronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease
Doody, R. S., Dunn, J. K., Clark, C. M., Farlow, M., Foster, N. L., Liao, T., Gonzales, N., Lai, E., & Massman, P. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051272 · Cited by 118
Cited by
Andersen, C. K., Wittrup-Jensen, K. U., Lolk, A., Andersen, K., & Kragh-Sørensen, P. (2004) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-2-52 · Cited by 365
Neuropsychological differences between frontotemporal dementia and Alzheimer’s disease: a review
Harciarek, M., & Jodzio, K. (2005) · Neuropsychology Review · doi:10.1007/s11065-005-7093-4 · Cited by 101
“As the disease progresses, other symptoms like agnosia, aphasia, and apraxia may appear (second stage); thus eventually progressing to a more severe dementia, with weight loss, motor impairment, and death (third stage) (Bullock and Hammond, 2003).”
BackgroundEfficacy and Safety of Memantine in Moderate-to-Severe Alzheimer Disease: The Evidence to Date
Bullock, R. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000201847.29836.a5 · Cited by 89
“Worsening of function over time leads to a loss of independence and, eventually, institutionalization is often required.(1) Very advanced AD is a terminal illness requiring palliative treatment approaches similar to those used for advanced cancer and other serious health conditions.”
BackgroundSelf-citationAlzheimer's disease: cerebral glaucoma?
Wostyn, P., Audenaert, K., & De Deyn, P. P. (2010) · Medical Hypotheses · doi:10.1016/j.mehy.2009.12.019 · Cited by 51
Metadata
- Authors
- Bullock, R., & Hammond, G.
- Venue
- Alzheimer Disease & Associated Disorders
- Published
- 2003-07
- Volume
- 17
- Issue
- SUPPLEMENT 3
- Pages
- S80-S85
- ISSN
- 0893-0341 (ISSN-L)
- OpenAlex
- W2090728193
- Cited by
- 61
- References
- 7
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Realistic Expectations: The Management of Severe Alzheimer Disease. https://app.cochat.ai/papers/10.1097/00002093-200307003-00004
- The paper
- Bullock, R., & Hammond, G. (2003). Realistic Expectations: The Management of Severe Alzheimer Disease. Alzheimer Disease & Associated Disorders. https://doi.org/10.1097/00002093-200307003-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.